Share on StockTwits

Canaccord Genuity raised their target price on shares of OraSure Technologies (NASDAQ:OSUR) from $10.00 to $11.00 in a report released on Thursday. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price target indicates a potential upside of 47.06% from the company’s current price.

Several other analysts have also recently commented on the stock. Analysts at Mizuho raised their price target on shares of OraSure Technologies from $9.00 to $10.00 in a research note on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at TheStreet downgraded shares of OraSure Technologies from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, analysts at Raymond James reiterated an “outperform” rating on shares of OraSure Technologies in a research note on Thursday, May 8th. They now have a $8.50 price target on the stock, down previously from $10.00. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. OraSure Technologies presently has an average rating of “Hold” and an average target price of $8.93.

Shares of OraSure Technologies (NASDAQ:OSUR) traded up 0.13% on Thursday, hitting $7.49. The stock had a trading volume of 495,222 shares. OraSure Technologies has a 52 week low of $3.75 and a 52 week high of $8.60. The stock has a 50-day moving average of $6.45 and a 200-day moving average of $6.66. The company’s market cap is $418.2 million.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.03. The company had revenue of $23.50 million for the quarter, compared to the consensus estimate of $23.28 million. During the same quarter in the previous year, the company posted ($0.18) earnings per share. The company’s revenue for the quarter was up 10.8% on a year-over-year basis. Analysts expect that OraSure Technologies will post $-0.23 EPS for the current fiscal year.

OraSure Technologies, Inc, is engaged in development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using the Company’s oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.